Dimerix (ASX:DXB) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 07, 2026)


ASX:DXB Dimerix Ltd ASX:DXB
32 GF Score
Price A$0.26
! 3 Warning Signs
View Full Analysis

What is Dimerix 5-Year Yield-on-Cost %?

Dimerix ASX:DXB -1.92% 32 5-Year Yield-on-Cost % is 0.00 as of Jul. 07, 2026. GuruFocus rates ASX:DXB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 152 Biotechnology companies, Dimerix ranks worse than 657894.08% on this metric.

Dimerix's yield on cost for the quarter that ended in Dec. 2025 was 0.00.


The historical rank and industry rank for Dimerix's 5-Year Yield-on-Cost % or its related term are showing as below:



ASX:DXB's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.665
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Dimerix  (ASX:DXB) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Dimerix 5-Year Yield-on-Cost % Related Terms

ASX:DXB vs VRTX, REGN, ALNY: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Dimerix's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dimerix 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dimerix's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Dimerix's 5-Year Yield-on-Cost % falls into.


ASX:DXB
32GF Score
Dimerix Ltd ASX:DXB
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dimerix 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Dimerix is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Dimerix (ASX:DXB) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 07, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Dimerix and its competitors. According to the industry distribution chart, Dimerix ranks #999999 out of 152 companies in the Biotechnology industry.
Is Dimerix's 5-Year Yield-on-Cost % too high?
Dimerix's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Dimerix ranks #999999 out of 152 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Dimerix has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Dimerix's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Dimerix ranks #999999 out of 152 companies for 5-Year Yield-on-Cost %. This places Dimerix in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.67, based on 152 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Dimerix and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dimerix's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimerix stock overvalued right now?
Dimerix (ASX:DXB) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Dimerix's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Dimerix (ASX:DXB), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dimerix Business Description

Address 425 Smith Street, Fitzroy, VIC, AUS, 3065
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.
32GF Score

Get the complete analysis for ASX:DXB

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.26
Price